Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
Adjuvanted immunogenic compositions with conjugated pneumococcal capsular saccharide antigens and a saponin-containing liposomal adjuvant address the limitations of current pneumococcal vaccines by providing broader protection against pneumococcal serotypes, including those not covered by existing vaccines.
Patent Information
- Application Number
- PCT/IB2024/058829
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-14
- Filing Date
- 2024-09-11
- Publication Date
- 2025-03-20
AI Technical Summary
Current pneumococcal vaccines, such as Prevnar 13 and Vaxneuvance, do not provide adequate protection against serotypes not covered by these vaccines, and there is a concern for serotype replacement over time due to antibiotic resistance and vaccine introduction.
Development of adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens (glycoconjugates) and a saponin-containing liposomal adjuvant, which induce an immune response against additional Streptococcus pneumoniae serotypes, including those not covered by existing vaccines.
The proposed immunogenic compositions provide enhanced protection against a broader range of pneumococcal serotypes, including those not covered by existing vaccines, while maintaining immunity against serotypes currently protected by these vaccines.